Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) is a clinical-stage biotechnology company developing cell and gene therapies that incorporate engineered Gene Circuits. This news page aggregates company announcements, scientific updates, and corporate disclosures so readers can follow how Senti Bio advances its Gene Circuit platform and clinical programs over time.
A major focus of Senti Bio’s news flow is SENTI-202, its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy product candidate. Company releases describe ongoing Phase 1 clinical evaluation of SENTI-202 in adults with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome. Updates have highlighted clinical and pharmacodynamic data, presentations at the American Society of Hematology (ASH) Annual Meeting, and FDA designations such as Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation.
Visitors can also expect news on Senti Bio’s participation in investor and scientific conferences, quarterly financial result announcements, and communications about its broader Gene Circuit platform. These items provide context on how the company positions its synthetic biology approach, preclinical work in NK and T cells, and efforts to explore Gene Circuits in other modalities and disease areas through partnerships.
For investors and observers tracking SNTI, this page offers a centralized view of press releases and related information, from clinical data readouts and regulatory milestones to corporate presentations. Checking this feed periodically can help users understand the evolution of Senti Bio’s pipeline and its activities within the cell and gene therapy landscape.
Senti Bio (Nasdaq: SNTI) will host a conference call and webcast on Tuesday, December 9, 2025 at 8:00 AM ET to discuss updated clinical results from SENTI-202 being presented at the ASH Annual Meeting.
Presenters include Timothy Lu, MD, PhD (CEO, co‑founder), Kanya Rajangam, MD, PhD (President, Head of R&D, CMO) and external investigator Nosha Farhadfar, MD from Sarah Cannon Transplant & Cellular Therapy Program. Investors can join by phone or via webcast on the company Investors Events page; the webcast will be archived for 90 days after the live event.
Senti Biosciences (Nasdaq: SNTI) reported third-quarter 2025 results and confirmed a clinical data readout for the Phase 1 SENTI-202 study in acute myeloid leukemia at the American Society of Hematology (ASH) Annual Meeting on December 6-9, 2025.
Key figures: cash and cash equivalents $12.2M as of September 30, 2025 (vs. $48.3M at year-end 2024), R&D $10.5M, G&A $6.4M, and net loss $18.1M or $0.69 per share for Q3 2025. Company will present updated SENTI-202 clinical and correlative data and host a webcast during ASH.
Senti Bio (Nasdaq: SNTI) will present updated clinical results for SENTI-202, a first‑in‑class CD33/FLT3 & not EMCN logic‑gated off‑the‑shelf CAR NK cell therapy, at the ASH Annual Meeting, Dec 6–9, 2025.
The company announced two presentations on Dec 8, including an oral session (abs25-10130) at 5:45–6:00 PM and a poster (abs25-2711) at 6:00–8:00 PM. Reported highlights include deep, durable clinical remissions, a strong safety profile, and pharmacodynamic data showing selective killing of leukemic blasts and leukemic stem cells while sparing healthy hematopoietic stem and progenitor cells. A live webcast will accompany the ASH presentations.
Senti Biosciences (Nasdaq: SNTI) announced that CEO and co‑founder Timothy Lu, MD, PhD will present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025 in New York.
The live webcast of the presentation will be available on the company’s Investors > Events page and management will be available for one‑on‑one investor meetings for registered attendees.
Senti Biosciences (Nasdaq: SNTI) will present in person at BioJapan October 8-10, 2025. The presentation by Timothy Lu, MD, PhD, CEO and co-founder, is scheduled for Thursday, October 9 at 11:30 AM JST on Presentation Stage C at PACIFICO Yokohama Convention Center in Yokohama, Japan.
Management will be available for one-on-one investor meetings with qualified registered attendees and will host an exhibition booth at D-53. For participation details, refer to the conference website.
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, will participate in the upcoming MedInvest Biotech & Pharma Conference in Palo Alto, California.
Dr. Kanya Rajangam, President, Head of Research & Development and Chief Medical Officer, will deliver a presentation on Wednesday, September 24, 2025, at 9:55 AM PT. The management team will also be available for one-on-one meetings with qualified investors attending the conference.
A live webcast of the presentation will be accessible through the Events page in the Investors section of sentibio.com.
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
Co-Founder and CEO Dr. Timothy Lu will deliver a presentation on September 8, 2025, at 2:00 PM ET in New York. The company's management will also be available for one-on-one meetings with qualified investors attending the conference. A live webcast of the presentation will be accessible through Senti Bio's website and archived for 90 days.
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies through its Gene Circuit platform, has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech.
The virtual presentation will be delivered by Timothy Lu, M.D., Ph.D., the company's Co-Founder and Chief Executive Officer, on Tuesday, August 19, 2025, at 2:20 PM ET. The event is part of a broader virtual conference running from August 19-21, 2025.
Senti Biosciences (NASDAQ:SNTI) participated in a Virtual Investor segment to discuss the Phase 2 dose selection for SENTI-202, their Logic Gated off-the-shelf CAR-NK cell therapy. The presentation was led by Dr. Kanya Rajangam, President, Head of R&D and Chief Medical Officer.
SENTI-202 is being developed as a potential first-in-class treatment for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The discussion focused on the recently announced recommended Phase 2 dosing schedule for the clinical trial.
Senti Biosciences (NASDAQ:SNTI), a clinical-stage biotech company, has reported its Q2 2025 financial results and provided key updates on its SENTI-202 program for Acute Myeloid Leukemia (AML). The company has completed the dose-finding phase and confirmed the recommended Phase 2 dose (RP2D) in its ongoing Phase 1 clinical trial. SENTI-202 received FDA Orphan Drug Designation for AML treatment.
Financial highlights include cash position of $21.6M as of June 30, 2025 (down from $48.3M in December 2024), R&D expenses of $10.0M (up $0.8M YoY), and G&A expenses of $6.8M (up $2.6M YoY). The company reported a net loss of $14.7M ($0.56 per share) for Q2 2025. Additionally, Senti Bio secured a $1.0M grant from CIRM for SENTI-202's clinical development.